Ardelyx stock
ARDXNASDAQArdelyx, Inc., HealthcareISIN US0396971071
34Score 34 out of 100, Weak
Price and trend
42 / 100
Price history
−48% in one yearThe chart shows daily closes over 12 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 39% below it.
Since June 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 52).
The price is 61% below its 52-week high. Largest decline in 12 years: 95% (December 2014 to December 2018).
Chart figures for advanced users
- SMA 50$3.29
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$5.13
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)52
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$2.88
- The lowest closing price of the last twelve months.
- Resistance$7.99
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Ardelyx, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $784.28M, is number 206 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $407.32M (up 22.1% year on year) and a loss of $61.6M.
- For fiscal 2026, analysts expect on average revenue of $482.24M (up 18.4%) and adjusted earnings per share of −$0.19.
Show more
- MEQIRI Score 34 out of 100 (Weak): rank 622 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 121.9% a year since 2020, Biotechnology median 19.4%.Growth 70
- More cash than debtCash $285.34M, financial debt $256.34M.
Weaknesses
- DilutionShare count up 169% since 2020.Capital allocation 18
- Loss-makingLoss of $55.47M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$15.96M over the last 12 months.Fundamentals 17
Its standout strength is growth, while capital allocation and fundamentals hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredA fair value is not meaningful here, so the signal follows the valuation grade.
Valuation metrics
The model puts the fair value at more than four times the share price. That says more about the assumptions than about the company, so a fair value is not meaningful here and the valuation relies on the P/E and the other metrics.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 17.6% on the twelve months before. Revenue has grown strongly since 2013, at around 25% per year. From 2013 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 90%, operating −10%, net −15%. From 2013 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 18 Feb 2027in 97 days
- Last reported
- 3 Nov 2026EPS reported $0.00 (expected −$0.02)above expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 25.2% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$0.19−4.7%
- Revenue
- $482.24M−1.3%
- Earnings per share
- $0.19−25.2%
- Revenue
- $608.01M−2.6%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook lowered
Share price after the results: −18.5%2026 IBSRELA revenue guidance lowered to $350 to $370 million; the other revenue guidance of $110 to $120 million is reiterated and operating expenses are now expected below $500 million.
“Starting with 2026, for IBSRELA, taking into consideration the current environment and our proactive initiatives to increase access and fulfillment, we have made the prudent decision to lower our full-year 2026 guidance for IBSRELA to a range of $350 million to $370 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 8 insiders sold, $2.23M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Hohenleitner SusanSale
21 Aug 2026, Chief Financial Officer
- Shares
- 1,558
- Price
- $3.86
- Value
- $6,009
- Reilly Joseph JamesSale
21 Aug 2026, See Remarks
- Shares
- 3,982
- Price
- $3.86
- Value
- $15,358
- Bishop John ESale
21 Aug 2026, See Remarks
- Shares
- 19,750
- Price
- $3.86
- Value
- $76,174
Show 17 more
- Brady James ParkerSale
21 Aug 2026, Chief Human Resources Officer
- Shares
- 15,136
- Price
- $3.86
- Value
- $58,378
- Foster Eric DuaneSale
21 Aug 2026, Chief Commercial Officer
- Shares
- 8,562
- Price
- $3.86
- Value
- $33,023
- Kelliher MikeSale
21 Aug 2026, Chief Business Officer
- Shares
- 7,758
- Price
- $3.86
- Value
- $29,922
- Williams Laura ASale
21 Aug 2026, Chief Patient Officer
- Shares
- 10,739
- Price
- $3.86
- Value
- $41,419
- Raab MichaelSale
21 Aug 2026, President & CEO
- Shares
- 58,574
- Price
- $3.86
- Value
- $225,914
- Raab MichaelSale
15 Jul 2026, President & CEO
- Shares
- 41,668
- Price
- $5.06
- Value
- $210,923
- Williams Laura ASale
18 Jun 2026, Chief Patient Officer
- Shares
- 81,898
- Price
- $5.99
- Value
- $490,487
- Raab MichaelSale
15 Jun 2026, President & CEO
- Shares
- 41,666
- Price
- $5.67
- Value
- $236,346
- Reilly Joseph JamesSale
21 May 2026, See Remarks
- Shares
- 3,719
- Price
- $6.27
- Value
- $23,309
- Hohenleitner SusanSale
21 May 2026, Chief Financial Officer
- Shares
- 1,455
- Price
- $6.27
- Value
- $9,119
- Bishop John ESale
21 May 2026, See Remarks
- Shares
- 2,306
- Price
- $6.27
- Value
- $14,453
- Brady James ParkerSale
21 May 2026, Chief Human Resources Officer
- Shares
- 1,846
- Price
- $6.27
- Value
- $11,570
- Foster Eric DuaneSale
21 May 2026, Chief Commercial Officer
- Shares
- 7,998
- Price
- $6.27
- Value
- $50,127
- Kelliher MikeSale
21 May 2026, Chief Business Officer
- Shares
- 7,248
- Price
- $6.27
- Value
- $45,427
- Williams Laura ASale
21 May 2026, Chief Patient Officer
- Shares
- 6,989
- Price
- $6.27
- Value
- $43,804
- Raab MichaelSale
21 May 2026, President & CEO
- Shares
- 54,748
- Price
- $6.27
- Value
- $343,133
- Raab MichaelSale
15 May 2026, President & CEO
- Shares
- 41,666
- Price
- $6.28
- Value
- $261,612
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Ardelyx
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 34
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- AnnexonANNX $812.47M36
- Lexicon PharmaceuticalsLXRX $810.33M39
- Arbutus BiopharmaABUS $798.37M66
- AlumisALMS $793.44M38
- Olema PharmaceuticalsOLMA $760.22M34
- GubraGUBRA.CO $738.91M43
- DBV TechnologiesDBV.PA $738.12M40
- Aura BiosciencesAURA $737.34M41
ETFs that hold Ardelyx
Held by 11 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.05% | 0.35% | €1.25B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.03% | 0.30% | €4.28B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.02% | 0.30% | €2.22B |
Show 5 more
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.02% | 0.30% | €185.82M |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.01% | 0.35% | €8.27B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.01% | 0.43% | €2.5B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.01% | 0.10% | €395.74M |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.00% | 0.30% | €964.08M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Jun 2015)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.